No retraction, correction or concern found when last checked on Oct 17, 2026.

NLRP3 Inflammasome in Neurological Diseases, from Functions to Therapies

Limin Song, Lei Pei, Shanglong Yao and 2 more

Frontiers in Cellular Neuroscience · 2017 · Review

doi:10.3389/fncel.2017.00063

Abstract

Neuroinflammation has been identified as a causative factor of multiple neurological diseases. The nucleotide-binding oligomerization domain-, leucine-rich repeat- and pyrin domain-containing 3 (NLRP3) inflammasome, a subcellular multiprotein complex that is abundantly expressed in the central nervous system (CNS), can sense and be activated by a wide range of exogenous and endogenous stimuli such as microbes, aggregated and misfolded proteins, and adenosine triphosphate, which results in activation of caspase-1. Activated caspase-1 subsequently leads to the processing of interleukin-1β (IL-1β) and interleukin-18 (IL-18) pro-inflammatory cytokines and mediates rapid cell death. IL-1β and IL-18 drive inflammatory responses through diverse downstream signaling pathways, leading to neuronal damage. Thus, the NLRP3 inflammasome is considered a key contributor to the development of neuroinflammation. In this review article, we briefly discuss the structure and activation the NLRP3 inflammasome and address the involvement of the NLRP3 inflammasome in several neurological disorders, such as brain infection, acute brain injury and neurodegenerative diseases. In addition, we review a series of promising therapeutic approaches that target the NLRP3 inflammasome signaling including anti-IL-1 therapy, small molecule NLRP3 inhibitors and other compounds, however, these approaches are still experimental in neurological diseases. At present, it is plausible to generate cell-specific conditional NLRP3 knockout (KO) mice via the Cre system to investigate the role of the NLRP3 inflammasome, which may be instrumental in the development of novel pharmacologic investigations for neuroinflammation-associated diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Neuroinflammation is a fundamental innate immune response in the central nervous system (CNS) by which the brain and spinal cord react to diverse pathogens and host-derived signals of cellular damage. Inflammatory responses are necessary steps for eliminating invading agents, clearing damaged cells and promoting tissue repair (Miwa et al.,; Tahara et al.,; Ito et al.,; Ribes et al.,; Szretter et al., ); however, uncontrolled neuroinflammation may lead to further tissue injury and neural dysfunction (Lazovic et al.,; Choi et al.,; Abo-Ouf et al., ). Therefore, it has become evident that neuroinflammation represents a significant cause of neurological deficits.

2Researchers have recently focused their attention on a group of subcellular multiprotein complexes referred to as inflammasomes (Martinon et al., ), whose formation and activation may be induced by a wide range of substances (Kanneganti et al.,; Mariathasan et al.,; Martinon et al.,; Sutterwala et al.,; Newman et al.,; Rathinam et al., ). In particular, the nucleotide-binding oligomerization domain-, leucine-rich repeat- and pyrin domain-containing 3 (NLRP3) inflammasome has gained considerable attention (Agostini et al., ). It is abundantly expressed in the CNS and may serve to detect noxious agents or irregularities in the cellular microenvironment (Halle et al.,; Yin et al.,; Jha et al.,; Geldhoff et al.,; Yang et al., ). Activated NLRP3 inflammasome leads to the activation of caspase-1, which mediates the production of interleukin-1β (IL-1β) and interleukin-18 (IL-18) pro-inflammatory cytokines and the initiation of a rapid form of cell death termed pyroptosis (Martinon et al.,; Kanneganti et al.,; Fink et al., ). IL-1β and IL-18, in turn, initiate multiple signaling pathways and drive inflammatory responses, which results in neuronal injury or death (Yatsiv et al.,; Bossù et al.,; Meissner et al.,; Wilms et al., ). Therefore, the NLRP3 inflammasome plays a crucial role in the development of inflammatory responses in the CNS. Moreover, emerging studies have revealed the involvement of NLRP3 signaling in several neurological disorders (Gris et al.,; Hoegen et al.,; Fann et al.,; Heneka et al.,; Johann et al., ).

3Herein, we describe the general principles involved in the structure and activation mechanisms of the NLRP3 inflammasome in the CNS, as well as the complex neuroinflammatory signaling pathways and consequences associated with NLRP3 inflammasome activation under the circumstances of brain infection, acute injury and neurodegenerative disorders. Finally, we conclude that NLRP3 inflammasome signaling may represent a promising therapeutic target for the treatment of neuroinflammation-associated neurological diseases.

Microglia and Astrocytes in Neuroinflammation

4Emerging evidence supports the notion that various pathological changes within the CNS elicit a prominent inflammatory reaction referred to as neuroinflammation. In the CNS parenchyma, microglia and astrocytes are the primary effectors of neuroinflammation (Karve et al.,; Shrivastava et al., ). Plasma membrane pattern recognition receptors (PRRs) expressed on glial cells play an important role in the activation of nuclear factor-κB (NF-κB) and mitogen-activated protein kinase inflammatory pathways (Tang et al.,; Heneka et al., ). In addition, microglial-astrocyte communication is highly important in CNS innate immunity.

5Microglia, the resident macrophage-like cells of the CNS, are derived from yolk-sac myeloid progenitors during the early stage of embryonic development (Kierdorf et al., ). They continually monitor and survey their assigned brain regions and participate in CNS development, neuroprotection, and the maintenance of hemostasis (Paolicelli et al.,; Nayak et al., ). Microglia express numerous PRRs that are responsible for the early recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), such as Toll-like receptors (TLRs), NOD-like receptors (NLRs), retinoic acid-inducible gene-I-like receptors and triggering receptor expression on myeloid cells 2 (TREM2; Shah et al.,; Kumar et al.,; Hu et al.,; Fu et al., ). Microglial cells are considered the earliest responders to pathological insults on the CNS (Becher et al.,; Saijo et al., ). Under non-pathological conditions, microglial cells have a highly ramified appearance. Upon detecting environmental challenges, such as brain injury, infection, or protein aggregates, microglia become rapidly “activated” and transform to an ameboid appearance with increased expression of major histocompatibility complex molecules and other markers (Rock et al.,; Kettenmann et al., ). Proliferation and migration of microglial cells also occur (Byrnes and Faden, ). Moderate microglial responses exert protective effects on the CNS in some circumstances (Lalancette-Hébert et al., ). Nevertheless, over-activated microglia can lead to neuroinflammation, oxidative stress and neuronal dysfunction due to the excess production of a wide range of cytotoxic factors, such as tumor necrosis factor-α (TNF-α), IL-1β, IL-18, IL-6, reactive oxygen species (ROS) and nitric oxide (NO; Moss and Bates,; Heneka and O’Banion,; Nayak et al., ). Moreover, the interaction between microglia and other immune cells results in secondary inflammatory responses. Recent findings have involved microglia activation in the initiation and maintenance of inflammatory responses in the context of infectious brain diseases, acute CNS injury and several neurodegenerative diseases (Aoki et al.,; Fellner et al.,; Elmore et al.,; Liu et al.,; Kumar et al.,; Li D. et al.,; Xian et al., ).

6Similar to peripheral macrophages, several broad classifications of microglia M1, M2a, M2b and M2c have been identified in the literature (Geissmann et al.,; Franco and Fernández-Suárez, ). “Classically activated” M1 microglia, which exhibit an ameboid appearance, strong phagocytic capability and high mobility, are characterized by the generation and secretion of large amounts of pro-inflammatory mediators and high levels of oxidative production (Loane and Byrnes,; Zhang et al., ). Generally, “alternatively activated” M2 microglia exhibit a hyper-ramification appearance (Cherry et al., ) and produce plenty of anti-inflammatory cytokines, neurotrophic factors, and extracellular matrix molecules (David and Kroner,; Michell-Robinson et al., ). Therefore, M2 microglia are primarily associated with the resolution of inflammation and tissue repair. Three subclasses of M2 microglia exhibit slight differences in cellular markers and functions. M2b microglia are characterized by large amounts of pro-inflammatory cytokine generation and by high IL-10 and low IL-12 expression (Ferrante et al.,; Orihuela et al., ), which allows them to be able to shift to a mixture of M1 and M2a/b.

7Substantial numbers of astrocytes are present in the CNS parenchyma, and they perform a diverse array of functions including glutamate uptake, fuel provision, synaptogenesis, structural support and immune defense (Brown and Ransom,; Perea et al.,,; Barreto et al., ). Astrocytes display a great degree of heterogeneity in their morphology, lineage, anatomical locations and gene expression profile (Zhang and Barres,; Sosunov et al., ). Astrocytes are equipped with various innate immune receptors, and they directly respond to different types of CNS insults with hypertrophy and hyperplasia, a process referred to as astrogliosis. Astrocytes, however, are involved in the formation of compact astrocytic scars by forming and orienting long processes toward the core of severely damaged sites (Cregg et al., ). Under normal circumstances, reactive astrogliosis and scar formation are essential for confining CNS inflammation to the lesion epicenter, protecting neural networks and promoting repair of the blood–brain barrier (BBB; Pekny and Nilsson,; Sofroniew,, ). However, under pathological conditions, astrogliosis can interfere with neurite growth and regeneration (Silver and Miller,; Anderson et al.,; Cregg et al., ). Moreover, reactive astrocytes produce numerous pro-inflammatory mediators, such as cytokines, chemokines and NO, which makes them essential for exacerbating inflammatory responses. Notably, by regulating specific signaling events, astrogliosis can exert either potent pro-inflammatory effects or essential anti-inflammatory effects.

NLRP3 Inflammasome

8The NLRP3 inflammasome was first characterized in Muckle-Wells Autoinflammatory Disorder (Martinon et al.,; Agostini et al., ). NLRP3 inflammasome can sense various stimuli and form a molecular platform for caspase-1 activation, which leads to the processing and release of IL-1β and IL-18 and eventually potentiates inflammatory responses that are involved in multiple infectious, inflammatory and immune diseases (Sutterwala et al.,; Willingham et al.,; Halle et al.,; Masters et al.,; Walsh et al., ). Thus, the NLRP3 inflammasome is of crucial importance in the development of both acute and chronic inflammatory responses.

9The NLRP3 inflammasome mainly consists of a cytosolic sensor molecule NLRP3, an adaptor protein apoptosis-associated speck-like protein containing a caspase activating recruitment domain (ASC), and a cysteine protease pro-caspase-1 as the effector molecule (Agostini et al.,; see Figure 1).

10NLRP3 contains a C-terminal leucine-rich repeat (LRR) domain, a conserved central nucleotide binding and oligomerization domain (NOD or NACHT), and an N-terminal pyrin-only domain (PYD; Anderson et al., ). The LRR domain recognizes PAMPs and other ligands, maintains the NLRP inactive state, and mediates protein-protein interactions (Meng et al.,; O’Connor et al.,; Hoffman et al., ). The NACHT domain, with ATPase activity, is essential for protein self-oligomerization during the inflammasome assembly process (Duncan et al., ). The PYD enables protein-protein homotypic interactions between NLRP and the bipartite adapter ASC (Liepinsh et al., ).

11ASC consists of an N-terminal PYD and a C-terminal caspase activation and recruitment domain (CARD; Masumoto et al., ). ASC binds to the upstream NLRP3 through a homotypic PYD-PYD domain interaction, which results in ASC dimer assembly into a large speck-like structure (Dowds et al., ). ASC interacts with pro-casapase-1 via the CARD domain (Srinivasula et al., ).

12Caspase-1 is present as a catalytically inactive precursor pro-caspase-1 in unstimulated cells. Pro-caspase-1 recruitment, which is mediated by ASC, contributes to caspase-1 oligomerization and auto-proteolytic conversion of the pro-enzyme into its active form (Agostini et al., ). The active caspase-1 fragments elicit the maturation and secretion of pro-inflammatory cytokines IL-1β and IL-18, which belong to the IL-1β family and mediate subsequent immune responses (Keller et al., ).

13Caspase-1 activation also induces a form of inherent inflammatory cell death, referred to as pyroptosis, which is characterized by rapid plasma-membrane rupture, DNA fragmentation, and the release of pro-inflammatory cytosolic contents into the extracellular space (Bergsbaken et al., ). Pyroptosis is both morphologically and mechanistically different from apoptosis and other forms of cell death. Recent studies have identified that activated caspase-1 cleaves gasdermin D (GSDMD) to generate the gasdermin-N domain of GSDMD (GSDMD-NT), which can directly bind phosphoinositides and cardiolipin (Shi J. et al.,; Ding et al.,; Liu et al., ). GSDMD-NT then associates with the plasma membrane and oligomerizes to form non-selective pores, which triggers cell swelling and lysis (Chen et al.,; Liu et al., ). Both neurons and glial cells may trigger this process of cell death in response to a wide range of pathological stimuli (Adamczak et al.,; Tan et al.,; Kim et al., ).

Activation and Regulation of the NLRP3 Inflammasome

14The NLRP3 inflammasome is the most extensively investigated inflammasome, and it is present in microglia and astrocytes in the CNS (Cho et al.,; Lu et al.,; Zendedel et al., ). It remains debated whether neurons express NLRP3 (Fann et al.,; Yang et al.,; Kaushal et al., ). In vitro studies suggest that the basal level of NLRP3 in resting cells is not sufficient to activate the inflammasome. It is widely accepted that successful NLRP3 inflammasome activation requires a two-checkpoint signal process. A priming signal is provided by the NF-κB-activating stimuli to transcriptionally enhance the expression of NLRP3 and pro-IL-1β (Bauernfeind et al., ). Many TLR and NLR ligands, as well as endogenous cytokines such as IL-1α, have been demonstrated to prime cells. The subsequent activating signal is provided by various NLRP3-activating agents to promote the formation of the inflammasome complex. A wide range of exogenous and endogenous stimuli including PAMPs, aggregated and misfolded proteins, ATP and crystalline substances induce NLRP3 activation (Mariathasan et al.,; Martinon et al.,; Halle et al.,; Demento et al.,; Duncan et al.,; Shi F. et al., ).

15Given the broad array of NLRP3 activators, NLRP3 appears to sense the disturbance of cellular homeostasis rather than directly react to these stimuli. To elucidate this, researchers have proposed several theories as follows: (1) low intracellular K+ concentration may play a major role in common signal transduction for NLRP3 activation (Pétrilli et al.,; Marina-García et al.,; Karmakar et al., ); (2) endo-lysosomal destabilization induces the release of cathepsins into the cytosol, which may directly activate NLRP3 (Hornung et al.,; Sharp et al.,; Bruchard et al., ); (3) ROS, mitochondrial DNA and phospholipid cardiolipin released from damaged mitochondria activate NLRP3 (Zhou et al.,,; Subramanian et al., ); (4) Ca2+ flux and the Ca2+-dependent signaling trigger the assembly of NLRP3 inflammasome (Feske et al.,; Lee et al.,; Murakami et al., ).

16The activity of NLRP3 is finely regulated through distinct mechanisms. Recent studies have revealed that BRCC-3, double-stranded RNA-dependent protein kinase, death-associated protein kinase 1 and Bruton’s tyrosine kinase function as endogenous positive regulators of NLRP3 inflammasome activity (Chuang et al.,; Juliana et al.,; Lu et al.,; Py et al.,; Ito et al., ). A member of the NIMA-related kinase (NEK) family, NEK7 has been shown to directly bind to the LRR domain of NLRP3 and act downstream of K+ efflux and ROS generation to promote the assembly of NLRP3 inflammasome (He et al.,; Schmid-Burgk et al.,; Shi et al., ). Nevertheless, autophagy, microRNAs, CARD-only proteins, pyrin-only proteins and NO act as endogenous negative regulators of NLRP3 (Saitoh et al.,; Hernandez-Cuellar et al.,; Shi C. S. et al.,; Mishra et al.,; de Almeida et al.,; Qin et al.,; Yang et al., ).

Effects of Inflammasome Activation on Neuroinflammation

17The NLRP3/caspase-1/IL-1 axis has emerged as a critical signaling pathway of the innate immune system in the CNS (Rosenzweig et al.,; see Figure 2). The abundance of caspase-1 has been identified in the context of neuroinflammation-related disorders (Sifringer et al.,; de Rivero Vaccari et al., ). IL-1β and IL-18 are cytokines that are matured by the NLRP3 inflammasome. The involvement of IL-1β and IL-18 in neuroinflammation has long been speculated (Arend et al.,; Dinarello et al., ). High levels of IL-1β and IL-18 have been demonstrated in the cerebrospinal fluid (CSF), brain tissue and plasma of patients with CNS infection, brain injury and neurodegenerative diseases such as Alzheimer’s disease (AD) and multiple sclerosis (MS; Licastro et al.,; de Jong et al.,; Huang et al., ). Both IL-1β and IL-18 bind to their respective receptors on microglial cells, astrocytes, neurons and endothelial cells, thereby triggering a complex spectrum of signaling events, which results in secondary expression of multiple inflammation-associated genes. Notably, cytokine-mediated processes were shown to be involved in cognitive decline and have been verified to lead to long-term neuropsychiatric disorders (McAfoose and Baune, ).

18IL-1β signaling plays a major role in the initiation and continuation of the inflammatory reactions in the CNS in response to various adverse stimuli (Cannon, ). IL-1β contributes to modulating the integrity of the BBB, which results in the infiltration of peripheral immune cells into the CNS (Alvarez et al., ). IL-1β also stimulates the activation of microglia and astrocytes, which in turn activates CNS-infiltrated T cells and induces the generation of additional pro-inflammatory factors such as IL-6 and TNF-α, as well as neurotoxic mediators (Ferrari et al., ). Moreover, IL-1β indirectly recruits leukocytes by augmenting the expression of chemokines (Gosselin and Rivest, ). Several experimental studies have even demonstrated that over-expression of IL-1β mediates neuronal injury by regulating glutamate excitotoxicity (Hu et al.,; Fogal et al., ).

19IL-18 mainly stimulates T-helper (Th) cell-mediated immune responses by inducing the production of adhesion molecules, pro-inflammatory cytokines and chemokines in natural killer, Th1 and B cells (Nakahira et al.,; Bossù et al., ). IL-18 also activates signaling pathways in microglia, which results in increased caspase-1 expression and matrix metalloproteinases and pro-inflammatory cytokine production (Felderhoff-Mueser et al., ). In addition, IL-18 augments Fas ligand expression in glial cells, thereby exacerbating Fas-mediated neuronal cell death in the context of neuroinflammation. IL-18 thus converges two distinct immunological regulatory pathways of inflammatory reactions and cytotoxic effects.

20Pyroptosis is a highly inflammatory, programmed form of cell death. It is distinct from necrosis and apoptosis as the pathway is exclusively mediated by activated caspase-1 (Bergsbaken et al., ). So far, pyroptosis has been described in both glial cells and neurons (Alfonso-Loeches et al.,; Tan et al.,; Kim et al., ). Pyroptosis causes rapid rupture of the plasma membrane and excessive release of pro-inflammatory cytokines and chemokines such as TNF-α, IL-1β, IL-6 and CX3C-chemokine ligand 3, which may aggravate inflammatory mediator-induced neuronal death (Fink et al.,; Ramesh et al., ). As these factors have been shown to mediate the recruitment of other immune cells from peripheral circulation, plenty of leukocytes are attracted to the inflammation sites, and the subsequent inflammatory responses cause severe tissue damage in the CNS under neuropathological conditions (Koedel et al., ).

NLRP3 Inflammasome and Neurological Diseases

21Aberrant activation of NLRP3 inflammasome signaling has been demonstrated to contribute to pathology in a broad spectrum of neurological diseases (see Table 1).

Bacterial infection

22Streptococcus pneumoniae (S. pneumoniae) causes meningitis when it invades the CSF space. Studies of both murine models and patients have demonstrated that the NLRP3 inflammasome plays a central role in the pathologic progression of pneumococcal meningitis (Hoegen et al.,; Geldhoff et al., ). Pneumolysin, a pneumococcal pore-forming cytolysin, induced caspase-1-dependent pyroptotic cell death and IL-1β maturation through ATP-dependent lysosomal destabilization and ROS production (Kim et al., ). Excessive NLRP3 inflammasome activation led to extensive inflammatory responses and exacerbated tissue damage in the brain, as well as other adverse outcomes (Wu et al.,; Hoegen et al.,; Mitchell et al., ). Staphylococcus aureus (S. aureus) also induced NLRP3 inflammasome activation in microglia in an ATP- and cathepsin B-dependent manner (Hanamsagar et al., ). Moreover, priming microglia with conditioned media from Mycobacterium tuberculosis (Mtb)-infected macrophages, in combination with infection with Mtb, instigated robust activation of the NLRP3 inflammasome. Lowering intracellular K+ concentrations, lysosomal protease release and mitochondrial ROS generation were suggested to be upstream events of Mtb-induced NLRP3 activation (Lee et al., ). Listeria monocytogenes (LM) is the causative agent of several life-threatening diseases, including meningitis and septicemia (Roed et al.,; Thønnings et al., ). As NLRP3 is one of the major sensors of LM (Warren et al., ), it is plausible that NLRP3 inflammasome play a role in the pathology of LM-associated meningitis.

Viral Infection

23Japanese Encephalitis virus (JEV) represents a common cause of acute viral encephalitis. Microglia rapidly respond to JEV infection and secrete several pro- and anti-inflammatory cytokines, including IL-1β and IL-18. JEV triggers NLRP3 inflammasome activation through K+ efflux and ROS production, as shown in a murine model and Bv-2 microglial cells (Kaushik et al., ). It has been implicated that NLRP3 inflammasome signaling plays a crucial role in host protection during influenza virus challenge; however, prolonged NLRP3 inflammasome activation induces a hyper-inflammatory state and contributes to pathogenesis and mortality (Thomas et al.,; McAuley et al.,; Pinar et al.,; Tate et al., ). Additionally, the expression of NLRP3 was up-regulated in murine brains during influenza viral infection (Yu et al., ). Interestingly, the expression of NLRP3 inflammasome-associated genes was also increased in the brains of patients with HIV/AIDS (Walsh et al., ). An in vivo model of feline immunodeficiency viral infection and HIV-1 Vpr transgenic mice exhibited NLRP3 inflammasome activation with accompanying neuronal loss and neurological disorders (Walsh et al.,; Mamik et al., ).

Cerebral Ischemia

24The innate immune response plays a critical role in the overall pathogenesis of cerebral ischemia injury. Inflammatory cytokines released from activated microglia initiate downstream signaling cascades that eventually lead to neuronal cell loss following acute brain ischemia (Harari and Liao, ). NLRP3 protein was found to increase after experimental ischemic stroke, which was concomitant with high IL-1β and IL-18 levels and extensive neuronal and glial cell death (Lammerding et al., ). Interference of NLRP3 activation improved cerebral ischemia outcomes, as evidenced by reduced infarction volumes and decreased levels of neurovascular damage (Fann et al.,; Yang et al., ).

Traumatic Injury

25Traumatic brain injury (TBI) and spinal cord injury (SCI) are both debilitating conditions worldwide and are associated with poor prognosis (Levin and Diaz-Arrastia,; Witiw and Fehlings, ). In general, they result from insults by an external mechanical force (Xiong et al., ), which is characterized by both primary and secondary injury mechanisms. The primary injury is the immediate mechanical disruption of brain tissue. The secondary injury triggers cascades of cellular and molecular events over a prolonged time course (Werner and Engelhard,; Ji et al., ). IL-1β has been widely implicated in the progression of TBI and SCI. The protein levels of the NLRP3 inflammasome components were increased in TBI and SCI patients and in murine models (Adamczak et al.,; Liu et al.,; Zendedel et al., ). Notably, ASC neutralization substantially reduced the contusion volume in a rat model of TBI (de Rivero Vaccari et al., ). Pannexin1 channel, in addition to being linked to activation of the NLRP3 inflammasome, serves as a cell death effector during neuronal pyroptosis, which makes it a potential therapeutic target (Adamczak et al., ).

Hemorrhagic Stroke

26Intracerebral hemorrhage (ICH) is a devastating stroke subtype (Keep et al., ). The pathophysiology of ICH is characterized by the infiltration of systemic immune cells, the activation of microglia and the production of pro-inflammatory cytokines such as IL-1β (Wang and Doré, ). The expression of NLRP3 was increased in a mouse model of ICH, and the inhibition of NLRP3 attenuated neuroinflammation and improved neuronal function, which indicates the involvement of NLRP3 inflammasome in the pathogenesis of ICH (Ma et al.,; Yang et al.,; Yuan et al., ). ROS and the P2X purinergic receptor 7 (P2X7R) pathway may play roles in NLRP3 activation during ICH (Ma et al.,; Feng et al., ).

27Subarachnoid hemorrhage (SAH) is a fatal cerebrovascular disease with the highest mortality among all stroke subtypes (Bian et al.,; Keep et al., ). Early brain injury, which is highlighted by neuroinflammation, represents a key mechanism of SAH development (Sehba et al., ). NLRP3 inflammasome was found to be activated in a rat SAH model (Li J. et al.,; Shao et al., ). Pharmacological inhibition of P2X7R ameliorated brain edema and neurological deficits, which indicates a mechanism of the P2X7R pathway in NLRP3 activation after SAH (Chen et al., ).

Neurodegenerative Diseases

28Neurodegenerative diseases are always accompanied by chronic neuroinflammation with the excessive production of IL-1β and IL-18 pro-inflammatory cytokines, which has detrimental consequences for brain structure and function. The NLRP3 inflammasome is of particular importance in the development of inflammatory responses. To date, a pathogenic role of the NLRP3 inflammasome has been shown in several neurodegenerative diseases including AD, MS and amyotrophic lateral sclerosis (ALS). Whether the NLRP3 inflammasome contributes to the pathogenesis of Prion diseases remains debated.

29The expression of NLRP3 and caspase-1 is substantially increased in the brains of AD patients (Heneka et al.,; Saresella et al., ). It has become evident that extracellular deposition of β-amyloid (Aβ) peptides in senile plaques is the initiating event in AD. Aβ drives the release of mature IL-1β via activation of the NLRP3 inflammasome in microglia (Halle et al.,; Parajuli et al., ). NLRP3 or caspase-1 deficiency substantially attenuates spatial memory impairment and enhances Aβ clearance in AD transgenic mice (Heneka et al., ). According to a candidate gene study conducted among northern Han Chinese, two functional single-nucleotide polymorphisms (SNPs) in the NLRP3 gene (rs2027432 and rs10754558) had synergistic effects on late-onset AD risk (Tan et al., ). Moreover, CARD8 protein suppresses NLRP3 activity, and another study indicates that the p.C10X polymorphism of the CARD8 gene (rs2043211) predisposes people to AD (Fontalba et al., ).

MS

30MS is characterized by the demyelination of axons and chronic inflammation; experimental autoimmune encephalitis (EAE) is the most widely used rodent model for MS. The expression levels of caspase-1, IL-1β and IL-18 were increased in MS plaques and cells from MS patients (Huang et al.,; Inoue et al., ). NLRP3-deficient mice exhibited resistance to EAE, as evidenced by reduced demyelination and astrogliosis in the spinal cord (Gris et al., ). It has been suggested that the NLRP3 inflammasome is likely involved in EAE pathogenesis through the induction of chemokine-mediated recruitment of immune cells (Inoue et al., ). However, recent studies have shown that pertussis toxin, which is commonly injected as an adjuvant to increase EAE incidence, induced activation of a pyrin-dependent inflammasome (Dumas et al.,; Barclay and Shinohara, ), Therefore, the inflammasome sensor involved in MS/EAE might be not restricted to NLRP3.

ALS

31Mutations in human superoxide dismutase 1 lead to the formation of toxic misfolded protein aggregates, which play an important role in the pathogenesis ALS (Tsuda et al.,; Ioannides et al., ). Increased NLRP3, ASC, IL-1β, IL-18 and active caspase-1 levels were detected in both human ALS tissue and in murine models (Johann et al.,; Debye et al., ). Transactive response DNA-binding protein-43 (TDP-43) is considered a major component of intraneuronal aggregates in ALS patients (Arai et al., ). TDP-43 instigated NLRP3 inflammasome activation in microglia, which resulted in a pro-inflammatory signaling that is detrimental to motor neurons (Zhao et al., ).

Prion Diseases

32Prion diseases are caused by the conversion of cellular prion protein (PrPC) to the pathological isoform PrPSc through conformational changes (Shi F. et al., ). Aggregated PrPSc peptides lead to the activation of microglia and astrocytes, which results in the release of pro-inflammatory cytokines and neurotoxic factors (Tribouillard-Tanvier et al., ). PrP exposure up-regulated NLRP3 and ASC expression in microglia, and silencing of NLRP3 or ASC significantly reduced IL-1β production (Shi F. et al., ). However, a recent in vivo study using NLRP3- or ASC-deficient mice inoculated with scrapie prions demonstrated that NLRP3 and ASC were not involved in prion pathogenesis (Nuvolone et al., ). This discrepancy might be attributed to the different prion proteins used in these studies and the strain-specific features of prion diseases (Tixador et al.,; Ayers et al., ). More studies on other forms of prion diseases are needed to verify the involvement of the NLRP3 inflammasome.

Targeting the NLRP3 Inflammasome for the Treatment of Neurological Diseases

33The relevance of the NLRP3 inflammasome in human CNS pathologies has led to research on the possibilities of pharmacologically targeting the NLRP3 signaling pathways. To date, several advances have been made in the identification of exogenous compounds that may block IL-1 signaling or serve as inhibitors of NLRP3 inflammasome activation (White et al.,; see Figure 3); however, most compounds are in the early stages of development.

Anti-IL-1 Therapy

34Currently, anti-IL-1 therapies including interleukin-1 receptor antagonists (IL-1Ra) such as anakinra and specific monoclonal antibodies such as canakinumab have been approved for use in patients with auto-inflammatory disorders (Kuemmerle-Deschner et al., ). IL-1Ra administration reduced ischemic brain injury in a murine stroke model; however, it failed to exhibit long-term beneficial effects (Paolicelli et al., ). Anakinra is thought to have a preponderance for cryopyrin-associated periodic syndrome (CAPS)-associated neurologic disease because of its better CNS penetration. In addition, several other applications that target IL-1 or IL-1R are also under development (Dinarello et al., ). Despite their notable efficacy, anti-IL-1 drugs cannot resolve inflammasome-associated symptoms. Nevertheless, caspase-1-mediated pathways such as pyroptosis also drive disease pathology. These findings suggest that the direct blockade of inflammasome activation instead of merely neutralizing its downstream cytokines may be advantageous for controlling unwanted inflammatory reactions. Moreover, anti-IL-1 therapies are expensive and most of them may not readily penetrate tissues such as the brain.

Small Molecule Inhibitors of NLRP3

35Compounds with a sulfonylurea moiety appear to specifically inhibit activation of the NLRP3 inflammasome in the activation stage without affecting the NF-κB signaling-dependent priming stage (Lamkanfi et al.,; Coll et al., ). Glyburide was the first identified sulfonylurea moiety-containing drug to exhibit NLRP3-inhibitory activity in vitro; however, the required in vivo dose is associated with hypoglycemic effects. MCC950, a small-molecule compound that shares similarities with sulfonylurea, was shown to block ASC oligomerization induced by NLRP3, which makes it a highly potent and selective NLRP3 inhibitor. It effectively attenuated the inflammatory response in murine EAE models and ex vivo human samples (Coll et al., ). Its role in other neurological diseases requires additional investigation. Additionally, 16673-34-0, an intermediate substrate in glyburide synthesis, exhibited no effect on glucose metabolism and has been demonstrated to ameliorate myocardial ischemia/reperfusion (I/R) injury by inhibiting the formation of the NLRP3 inflammasome (Marchetti et al., ).

36The ketone metabolite β-hydroxybutyrate (BHB) was discovered to suppress NLRP3 inflammasome activation by inhibiting NLRP3-ASC oligomerization (Youm et al., ). Experiments showed that BHB decreased K+ efflux and endoplasmic reticulum stress (Youm et al.,; Bae et al., ). Furthermore, BHB is transported to brain parenchyma and plays a neuroprotective role under several pathological conditions (Orhan et al.,; Xie et al., ).

37A cysteinyl leukotriene receptor antagonist, which had been initially incorrectly termed as CRID3, was found to prevent caspase-1 activation in response to NLRP3 activators via direct inhibition of ASC oligomerization (Coll et al.,, ).

38INF4E is a newly synthesized compound that directly inhibits NLRP3 ATPase and specifically suppresses NLRP3 inflammasome activation (Cocco et al., ). It was shown to be protective against NLRP3-involved myocardial I/R in a rat model (Mastrocola et al., ). Further rigorous investigations are needed to evaluate the effects of INF4E on neurological diseases and its side effects.

393,4-methylenedioxy-β-nitrostyrene (MNS), a novel tyrosine kinase inhibitor, was reported to specifically and potently inhibit NLRP3 by directly targeting its NOD and LRR domain (He and Amer, ). According to a recent study, MNS prevented wound progression and improved healing in an experimental burn model (Xiao et al., ). The potent effects and minimal cytotoxicity of MNS make it an attractive candidate for the treatment of neurological diseases; however, studies investigating the role of MNS in the CNS are lacking (Hsieh et al., ).

Other Compounds that Target Specific Pathways

40Artemisinin, a well-established antimalarial drug, has been verified to exert anti-inflammatory effects via inhibition of the NF-κB signaling pathway. Artemisinin treatment also reduced the neuritic plaque burden and NLRP3 inflammasome activity in an AD transgenic mouse model (Shi et al., ). Studies have shown that artemisinin induces various side effects such as neurotoxicity, cardiotoxicity, embryotoxicity and allergic reactions when administered long-term (Efferth and Kaina,; Li and Hickman, ).

41The ATP-gated receptor P2X7R has been implicated in activation of the NLRP3 inflammasome (Deplano et al., ). P2X7R antagonist brilliant blue G (BBG) alleviated inflammation and improved neurological functions in a rodent model of SAH (Chen et al., ). BBG can penetrate the BBB at relatively low doses (Diaz-Hernandez et al., ). However, the use of P2X7R antagonists is controversial as these receptors are located in various cell types under pathological conditions and they may induce undesirable off-target effects (Franke et al., ).

42Probenecid, an FDA-approved drug for gout and hyperuricemia treatment, is a specific Pannexin1 channel blocker (Silverman et al., ). Probenecid inhibited NLRP3 activation in cultured neurons and astrocytes by providing a high extracellular concentration of K+ and decreased caspase-1 expression in the brains of aged rats (Mawhinney et al.,; Jian et al., ).

43A recent study reported that fenamate non-steroidal anti-inflammatory drugs (NSAIDs), including flufenamic acid and mefenamic acid, were neuroprotective in rodent models of AD (Daniels et al., ). Fenamates selectively inhibited NLRP3 by blocking volume-regulated anion channels (VRAC) in macrophages (Daniels et al., ). Fenamate NSAIDs target both VRAC/NLRP3 and cyclooxygenases, which makes them more efficacious than those targeting a single point in one inflammatory pathway. However, fenamate NSAIDs are associated with CNS toxicity, gastrointestinal adverse effects, nephrotoxicity, metabolic acidosis and prolongation of prothrombin time (Kingswell,; Redmond,; Frank et al.,; Court and Volans,; Kamour et al., ). It is important to reassess the benefit-risk profile of fenamate NSAIDs for treating NLRP3-associated disorders.

Outstanding Questions

44To date, several hurdles that require further investigation remain. Because the mechanisms of NLRP3 activation are differentially regulated at the cell and tissue levels (Toldo et al., ), it is necessary to characterize each step of the NLRP3 inflammasome cascades in specific cell types and brain regions under different pathological contexts. Additionally, the potential roles of NLRP3 signaling in the regulation of specific cell interactions that are involved in neuroinflammation remain to be elucidated.

Conclusions and Future Directions

45Major advances in the understanding of inflammasomes and inflammasome-mediated disorders have been made in the past decade. A spectrum of inflammatory responses has been associated with CNS pathological circumstances; thus, inflammasome activation likely exerts strong influences on various neurological diseases. Insufficient activation of inflammasome causes the host to become vulnerable to PAMPs and DAMPs; nevertheless, excessive inflammasome activation causes unfavorable outcomes in diverse diseases (Rathinam et al., ). Thus, the manipulation of a balanced and effective inflammasome-mediated inflammatory response is of paramount importance.

46Recent years, Cre-lox recombination-mediated neurogenetics has been developed as a useful technique to generate cell-specific gene knock-outs (KO) and knock-ins (Witten et al., ). Conditional autophagy gene KO mice have been recently generated by breeding autophagy-deficient mice with specific Cre drivers to investigate the regulatory role of autophagy in NLRP3 inflammasome activation in microglia (Cho et al., ). It is plausible to generate microglia/astrocyte conditional NLRP3 KO and knock-in mice through a similar genetic approach to study cell-specific interactions.

Author Contributions

47LS and LP made equal contribution to this work, performed literature review and drafted the article. SY revised and critically appraised the manuscript for intellectual content. YS and YW contributed to the revision and edition of the manuscript. All authors read and approved the final manuscript.

Conflict of Interest Statement

48The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 249

1.
Abo-Ouf H. Hooper A. W. White E. J. van Rensburg H. J. Trigatti B. L. Igdoura S. A. (2013 ). Deletion of tumor necrosis factor-α ameliorates neurodegeneration in Sandhoff disease mice. Hum. Mol. Genet. 22, 3960–3975.
Not in our library10.1093/hmg/ddt250
2.
Adamczak S. Dale G. de Rivero Vaccari J. P. Bullock M. R. Dietrich W. D. Keane R. W. (2012 ). Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J. Neurosurg. 117, 1119–1125.
Not in our library10.3171/2012.9.jns12815
3.
Adamczak S. E. de Rivero Vaccari J. P. Dale G. Brand F. J. III. Nonner D. Bullock M. R.. (2014 ). Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J. Cereb. Blood Flow Metab. 34, 621–629.
Not in our library10.1038/jcbfm.2013.236
4.
Agostini L. Martinon F. Burns K. McDermott M. F. Hawkins P. N. Tschopp J. (2004 ). NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 20, 319–325.
Not in our library10.1016/s1074-7613(04)00046-9
5.
Role of mitochondria ROS generation in ethanol-induced NLRP3 inflammasome activation and cell death in astroglial cells · 2014
No notice
6.
Alvarez J. I. Dodelet-Devillers A. Kebir H. Ifergan I. Fabre P. J. Terouz S.. (2011 ). The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 334, 1727–1731.
Not in our library10.1126/science.1206936
7.
Anderson M. A. Ao Y. Sofroniew M. V. (2014 ). Heterogeneity of reactive astrocytes. Neurosci. Lett. 565, 23–29.
Not in our library10.1016/j.neulet.2013.12.030
8.
Anderson J. P. Mueller J. L. Rosengren S. Boyle D. L. Schaner P. Cannon S. B.. (2004 ). Structural, expression and evolutionary analysis of mouse CIAS1. Gene 338, 25–34.
Not in our library10.1016/j.gene.2004.05.002
9.
Aoki E. Yano R. Yokoyama H. Kato H. Araki T. (2009 ). Role of nuclear transcription factor kappa B (NF-kappaB) for MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine)-induced apoptosis in nigral neurons of mice. Exp. Mol. Pathol. 86, 57–64.
Not in our library10.1016/j.yexmp.2008.10.004
10.
Arai T. Hasegawa M. Akiyama H. Ikeda K. Nonaka T. Mori H.. (2006 ). TDP-43 is a component of ubiquitinpositive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602–611.
Not in our library10.1016/j.bbrc.2006.10.093
11.
Arend W. P. Palmer G. Gabay C. (2008 ). IL-1, IL-18 and IL-33 families of cytokines. Immunol. Rev. 223, 20–38.
Not in our library10.1111/j.1600-065x.2008.00624.x
12.
Ayers J. I. Schutt C. R. Shikiya R. A. Aguzzi A. Kincaid A. E. Bartz J. C. (2011 ). The strain-encoded relationship between PrP replication, stability and processing in neurons is predictive of the incubation period of disease. PLoS Pathog. 7:e1001317.
Not in our library10.1371/journal.ppat.1001317
13.
β-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation · 2016
No notice
14.
Barclay W. Shinohara M. L. (2017 ). Inflammasome activation in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Brain Pathol. 27, 213–219.
Not in our library10.1111/bpa.12477
15.
Barreto G. E. Gonzalez J. Torres Y. Morales L. (2011 ). Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci. Res. 71, 107–113.
Not in our library10.1016/j.neures.2011.06.004
16.
Bauernfeind F. G. Horvath G. Stutz A. Alnemri E. S. MacDonald K. Speert D.. (2009 ). Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183, 787–791.
Not in our library10.4049/jimmunol.0901363
17.
Becher B. Prat A. Antel J. P. (2000 ). Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29, 293–304.
Not in our library10.1002/(sici)1098-1136(20000215)29:4<293::aid-glia1>3.3.co;2-1
18.
Bergsbaken T. Fink S. L. Cookson B. T. (2009 ). Pyroptosis: host cell death and inflammation. Nat. Rev. Microbiol. 7, 99–109.
Not in our library10.1038/nrmicro2070
19.
Bian L. H. Liu Y. F. Nichols L. T. Wang C. X. Wang Y. L. Liu G. F.. (2012 ). Epidemiology of subarachnoid hemorrhage, patterns of management and outcomes in China: a hospital-based multicenter prospective study. CNS Neurosci. Ther. 18, 895–902.
Not in our library10.1111/cns.12001
20.
Bossù P. Ciaramella A. Salani F. Vanni D. Palladino I. Caltagirone C.. (2010 ). Interleukin-18, from neuroinflammation to Alzheimer’s disease. Curr. Pharm. Des. 16, 4213–4224.
Not in our library10.2174/138161210794519147
21.
Brown A. M. Ransom B. R. (2007 ). Astrocyte glycogen and brain energy metabolism. Glia 55, 1263–1267.
Not in our library10.1002/glia.20557
22.
Bruchard M. Mignot G. Derangère V. Chalmin F. Chevriaux A. Végran F.. (2013 ). Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19, 57–64.
Not in our library10.1038/nm.2999
23.
Byrnes K. R. Faden A. I. (2007 ). Role of cell cycle proteins in CNS injury. Neurochem. Res. 32, 1799–1807.
Not in our library10.1007/s11064-007-9312-2
24.
Cannon J. G. (2000 ). Inflammatory cytokines in nonpathological states. News Physiol. Sci. 15, 298–303.
Not in our library10.1152/physiologyonline.2000.15.6.298
25.
Chen X. He W. T. Hu L. Li J. Fang Y. Wang X.. (2016 ). Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 26, 1007–1020.
Not in our library10.1038/cr.2016.100
26.
Chen S. Ma Q. Krafft P. R. Hu Q. Rolland W. II. Sherchan P.. (2013 ). P2X7R/cryopyrin inflammasome axis inhibition reduces neuroinflammation after SAH. Neurobiol. Dis. 58, 296–307.
Not in our library10.1016/j.nbd.2013.06.011
27.
Neuroinflammation and M2 microglia: the good, the bad, and the inflamed · 2014
No notice
28.
Cho M. H. Cho K. Kang H. J. Jeon E. Y. Kim H. S. Kwon H. J.. (2014 ). Autophagy in microglia degrades extracellular β-amyloid fibrils and regulates the NLRP3 inflammasome. Autophagy 10, 1761–1775.
Not in our library10.4161/auto.29647
29.
Striatal Neuroinflammation Promotes Parkinsonism in Rats · 2009
No notice
30.
Chuang Y. T. Lin Y. C. Lin K. H. Chou T. F. Kuo W. C. Yang K. T.. (2011 ). Tumor suppressor death-associated protein kinase is required for full IL-1β production. Blood 117, 960–970.
Not in our library10.1182/blood-2010-08-303115
31.
Cocco M. Garella D. Di Stilo A. Borretto E. Stevanato L. Giorgis M.. (2014 ). Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. J. Med. Chem. 57, 10366–10382.
Not in our library10.1021/jm501072b
32.
The Cytokine Release Inhibitory Drug CRID3 Targets ASC Oligomerisation in the NLRP3 and AIM2 Inflammasomes · 2011
Corrected
33.
Coll R. C. Robertson A. A. Chae J. J. Higgins S. C. Muñoz-Planillo R. Inserra M. C.. (2015 ). A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248–255.
Not in our library10.1038/nm.3806
34.
Court H. Volans G. N. (1984 ). Poisoning after overdose with non-steroidal anti-inflammatory drugs. Adverse Drug React. Acute Poisoning Rev. 3, 1–21.
Not in our library
35.
Cregg J. M. DePaul M. A. Filous A. R. Lang B. T. Tran A. Silver J. (2014 ). Functional regeneration beyond the glial scar. Exp. Neurol. 253, 197–207.
Not in our library10.1016/j.expneurol.2013.12.024
36.
Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models · 2016
No notice
37.
David S. Kroner A. (2011 ). Repertoire of microglial and macrophage responses after spinal cord injury. Nat. Rev. Neurosci. 12, 388–399.
Not in our library10.1038/nrn3053
38.
de Almeida L. Khare S. Misharin A. V. Patel R. Ratsimandresy R. A. Wallin M. C.. (2015 ). The PYRIN domain-only protein POP1 inhibits inflammasome assembly and ameliorates inflammatory disease. Immunity 43, 264–276.
Not in our library10.1016/j.immuni.2015.07.018
39.
de Jong B. A. Huizinga T. W. Bollen E. L. Uitdehaag B. M. Bosma G. P. van Buchem M. A.. (2002 ). Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J. Neuroinflammation 126, 172–179.
Not in our library10.1016/s0165-5728(02)00056-5
40.
de Rivero Vaccari J. P. Brand F. III. Adamczak S. Lee S. W. Perez-Barcena J. Wang M. Y.. (2016 ). Exosome-mediated inflammasome signaling after central nervous system injury. J. Neurochem. 136, 39–48.
Not in our library10.1111/jnc.13036
41.
de Rivero Vaccari J. P. Lotocki G. Alonso O. F. Bramlett H. M. Dietrich W. D. Keane R. W. (2009 ). Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J. Cereb. Blood Flow Metab. 29, 1251–1261.
Not in our library10.1038/jcbfm.2009.46
42.
Debye B. Schmülling L. Zhou L. Rune G. Beyer C. Johann S. (2016 ). Neurodegeneration and NLRP3 inflammasome expression in the anterior thalamus of SOD1(G93A) ALS mice. Brain Pathol. [Epub ahead of print].
Not in our library10.1111/bpa.12467
43.
Demento S. L. Eisenbarth S. C. Foellmer H. G. Platt C. Caplan M. J. Mark Saltzman W.. (2009 ). Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 27, 3013–3021.
Not in our library10.1016/j.vaccine.2009.03.034
44.
Dempsey C. Rubio Araiz A. Bryson K. J. Finucane O. Larkin C. Mills E. L.. (2017 ). Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav. Immun. 61, 306–316.
Not in our library10.1016/j.bbi.2016.12.014
45.
Deplano S. Cook H. T. Russell R. Franchi L. Schneiter S. Bhangal G.. (2013 ). P2X7 receptor-mediated Nlrp3-inflammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis. J. Leukoc. Biol. 93, 127–134.
Not in our library10.1189/jlb.0612284
46.
Diaz-Hernandez J. I. Gomez-Villafuertes R. León-Otegui M. Hontecillas-Prieto L. Del Puerto A. Trejo J. L.. (2012 ). In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer’s disease through GSK3β and secretases. Neurobiol. Aging 33, 1816–1828.
Not in our library10.1016/j.neurobiolaging.2011.09.040
47.
Dinarello C. A. Simon A. van der Meer J. W. (2012 ). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11, 633–652.
Not in our library10.1038/nrd3800
48.
Ding J. Wang K. Liu W. She Y. Sun Q. Shi J.. (2016 ). Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 573, 111–116.
Not in our library10.1038/nature18590
49.
Dowds T. A. Masumoto J. Zhu L. Inohara N. Núñez G. (2004 ). Cryopyrin-induced interleukin 1β secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC. J. Biol. Chem. 279, 21924–21928.
Not in our library10.1074/jbc.m401178200
50.
Dumas A. Amiable N. de Rivero Vaccari J. P. Chae J. J. Keane R. W. Lacroix S.. (2014 ). The inflammasome pyrin contributes to pertussis toxin-induced IL-1β synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis. PLoS Pathog. 10:e1004150.
Not in our library10.1371/journal.ppat.1004150
51.
Duncan J. A. Bergstralh D. T. Wang Y. Willingham S. B. Ye Z. Zimmermann A. G.. (2007 ). Cryopyrin/NALP3 binds ATP/dATP, is an ATPase and requires ATP binding to mediate inflammatory signaling. Proc. Natl. Acad. Sci. U S A 104, 8041–8046.
Not in our library10.1073/pnas.0611496104
52.
Duncan J. A. Gao X. Huang M. T. O’Connor B. P. Thomas C. E. Willingham S. B.. (2009 ). Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome. J. Immunol. 182, 6460–6469.
Not in our library10.4049/jimmunol.0802696
53.
Efferth T. Kaina B. (2010 ). Toxicity of the antimalarial artemisinin and its dervatives. Crit. Rev. Toxicol. 40, 405–421.
Not in our library10.3109/10408441003610571
54.
Ellis A. Grace P. M. Wieseler J. Favret J. Springer K. Skarda B.. (2016 ). Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury. Brain Behav. Immun. 58, 348–356.
Not in our library10.1016/j.bbi.2016.08.004
55.
Elmore M. R. Burton M. D. Conrad M. S. Rytych J. L. Van Alstine W. G. Johnson R. W. (2014 ). Respiratory viral infection in neonatal piglets causes marked microglia activation in the hippocampus and deficits in spatial learning. J. Neurosci. 34, 2120–2129.
Not in our library10.1523/jneurosci.2180-13.2014
56.
Fann D. Y. Lee S. Y. Manzanero S. Chunduri P. Sobey C. G. Arumugam T. V. (2013a ). Pathogenesis of acute stroke and the role of inflammasomes. Ageing Res. Rev. 12, 941–966.
Not in our library10.1016/j.arr.2013.09.004
57.
Fann D. Y. Lee S. Y. Manzanero S. Tang S. C. Gelderblom M. Chunduri P.. (2013b ). Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke. Cell Death Dis. 4:e790.
Not in our library10.1038/cddis.2013.326
58.
Felderhoff-Mueser U. Schmidt O. I. Oberholzer A. Bührer C. Stahel P. F. (2005 ). IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. 28, 487–493.
Not in our library10.1016/j.tins.2005.06.008
59.
Toll‐like receptor 4 is required for α‐synuclein dependent activation of microglia and astroglia · 2012
No notice
60.
P2X7R blockade prevents NLRP3 inflammasome activation and brain injury in a rat model of intracerebral hemorrhage: involvement of peroxynitrite · 2015
Corrected
61.
Ferrante C. J. Pinhal-Enfield G. Elson G. Cronstein B. N. Hasko G. Outram S.. (2013 ). The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling. Inflammation 36, 921–931.
Not in our library10.1007/s10753-013-9621-3
62.
Ferrari C. C. Depino A. M. Prada F. Muraro N. Campbell S. Podhajcer O.. (2004 ). Reversible demyelination, blood-brain barrier breakdown and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am. J. Pathol. 165, 1827–1837.
Not in our library10.1016/s0002-9440(10)63438-4
63.
Feske S. Skolnik E. Y. Prakriya M. (2012 ). Ion channels and transporters in lymphocyte function and immunity. Nat. Rev. Immunol. 12, 532–547.
Not in our library10.1038/nri3233
64.
Fink S. L. Bergsbaken T. Cookson B. T. (2008 ). Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc. Natl. Acad. Sci. U S A 105, 4312–4317.
Not in our library10.1073/pnas.0707370105
65.
Fogal B. Li J. Lobner D. McCullough L. D. Hewett S. J. (2007 ). System xc– activity and astrocytes are necessary for interleukin-1 β-mediated hypoxic neuronal injury. J. Neurosci. 27, 10094–10105.
Not in our library10.1523/jneurosci.2459-07.2007
66.
Fontalba A. Gutiérrez O. Llorca J. Mateo I. Berciano J. Fernández-Luna J. L.. (2008 ). Deficiency of CARD8 is associated with increased Alzheimer’s disease risk in women. Dement. Geriatr. Cogn. Disord. 26, 247–250.
Not in our library10.1159/000160956
67.
Franco R. Fernández-Suárez D. (2015 ). Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 131, 65–86.
Not in our library10.1016/j.pneurobio.2015.05.003
68.
Franke H. Günther A. Grosche J. Schmidt R. Rossner S. Reinhardt R.. (2004 ). P2X7 receptor expression after ischemia in the cerebral cortex of rats. J. Neuropathol. Exp. Neurol. 63, 686–699.
Not in our library10.1093/jnen/63.7.686
69.
Frank J. J. Wightkin W. T. Hubner J. W. (1983 ). Acute toxicity of nonsteroidal antiinflammatory agents: seizure following a mefenamic acid overdose. Drug Intell. Clin. Pharm. 17, 204–205.
Not in our library10.1177/106002808301700309
70.
Phagocytosis of Microglia in the Central Nervous System Diseases · 2014
No notice
71.
Geissmann F. Gordon S. Hume D. A. Mowat A. M. Randolph G. J. (2010 ). Unravelling mononuclear phagocyte heterogeneity. Nat. Rev. Immunol. 10, 453–460.
Not in our library10.1038/nri2784
72.
Geldhoff M. Mook-Kanamori B. B. Brouwer M. C. Troost D. Leemans J. C. Flavell R. A.. (2013a ). Inflammasome activation mediates inflammation and outcome in humans and mice with pneumococcal meningitis. BMC Infect. Dis. 13:358.
Not in our library10.1186/1471-2334-13-358
73.
Geldhoff M. Mook-Kanamori B. B. Brouwer M. C. Valls Seron M. Baas F. van der Ende A.. (2013b ). Genetic variation in inflammasome genes is associated with outcome in bacterial meningitis. Immunogenetics 65, 9–16.
Not in our library10.1007/s00251-012-0653-x
74.
Gosselin D. Rivest S. (2007 ). Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav. Immun. 21, 281–289.
Not in our library10.1016/j.bbi.2006.12.004
75.
Gris D. Ye Z. Iocca H. A. Wen H. Craven R. R. Gris P.. (2010 ). NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J. Immunol. 185, 974–981.
Not in our library10.4049/jimmunol.0904145
76.
Halle A. Hornung V. Petzold G. C. Stewart C. R. Monks B. G. Reinhecke L. T.. (2008 ). The NALP3 inflammasome is involved in the innate immune response to amyloid-β. Nat. Immunol. 9, 857–865.
Not in our library10.1038/ni.1636
77.
Hanamsagar R. Torres V. Kielian T. (2011 ). Inflammasome activation and IL-1β/IL-18 processing are influenced by distinct pathways in microglia. J. Neurochem. 119, 736–748.
Not in our library10.1111/j.1471-4159.2011.07481.x
78.
Harari O. A. Liao J. K. (2010 ). NF-κB and innate immunity in ischemic stroke. Ann. N Y Acad. Sci. 1207, 32–40.
Not in our library10.1111/j.1749-6632.2010.05735.x
79.
He Y. Amer A. O. (2014 ). Microbial modulation of host apoptosis and pyroptosis. Front. Cell. Infect. Microbiol. 4:83.
Not in our library10.3389/fcimb.2014.00083
80.
He Y. Zeng M. Y. Yang D. Motro B. Núñez G. (2016 ). NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature 530, 354–357.
Not in our library10.1038/nature16959
81.
Heneka M. T. O’Banion M. K. (2007 ). Inflammatory processes in Alzheimer’s disease. J. Neuroimmunol. 184, 69–91.
Not in our library10.1016/j.jneuroim.2006.11.017
82.
Heneka M. T. Kummer M. P. Latz E. (2014 ). Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 14, 463–477.
Not in our library10.1038/nri3705
83.
Heneka M. T. Kummer M. P. Stutz A. Delekate A. Schwartz S. Vieira-Saecker A.. (2013 ). NLRP3 is activated in Alzheimer’ disease and contributes to pathology in APP/PS1 mice. Nature 493, 674–678.
Not in our library10.1038/nature11729
84.
Hernandez-Cuellar E. Tsuchiya K. Hara H. Fang R. Sakai S. Kawamura I.. (2012 ). Cutting edge: nitric oxide inhibits the NLRP3 inflammasome. J. Immunol. 189, 5113–5117.
Not in our library10.4049/jimmunol.1202479
85.
Hoegen T. Tremel N. Klein M. Angele B. Wagner H. Kirschning C.. (2011 ). The NLRP3 inflammasome contributes to brain injury in pneumococcal meningitis and is activated through ATPdependent lysosomal cathepsin B release. J. Immunol. 187, 5540–5551.
Not in our library10.4049/jimmunol.1100790
86.
Hoffman H. M. Scott P. Mueller J. L. Misaghi A. Stevens S. Yancopoulos G. D.. (2010 ). Role of the leucine-rich repeat domain of cryopyrin/NALP3 in monosodium urate crystal-induced inflammation in mice. Arthritis Rheum. 62, 2170–2179.
Not in our library10.1002/art.27456
87.
Hornung V. Bauernfeind F. Halle A. Samstad E. O. Kono H. Rock K. L.. (2008 ). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat. Immunol. 9, 847–856.
Not in our library10.1038/ni.1631
88.
Hsieh P. W. Chang Y. T. Chuang W. Y. Shih H. C. Chiang S. Z. Wu C. C. (2010 ). The synthesis and biologic evaluation of anti-platelet and cytotoxic β-nitrostyrenes. Bioorg. Med. Chem. 18, 7621–7627.
Not in our library10.1016/j.bmc.2010.08.039
89.
Hu X. Liu G. Hou Y. Shi J. Zhu L. Jin D.. (2012 ). Induction of M2-like macrophages in recipient NOD-scid mice by allogeneic donor CD4+CD25+ regulatory T cells. Cell. Mol. Immunol. 9, 464–472.
Not in our library10.1038/cmi.2012.47
90.
Hu S. Sheng W. S. Ehrlich L. C. Peterson P. K. Chao C. C. (2000 ). Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 7, 153–159.
Not in our library10.1159/000026433
91.
Huang W. X. Huang P. Hillert J. (2004 ). Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Mult. Scler. 10, 482–487.
Not in our library10.1191/1352458504ms1071oa
92.
Inoue M. Williams K. L. Gunn M. D. Shinohara M. L. (2012 ). NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U S A 109, 10480–10485.
Not in our library10.1073/pnas.1201836109
93.
Ioannides Z. A. Henderson R. D. Robertson T. Davis M. McCombe P. A. (2016 ). When does ALS start? A novel SOD-1 p.Gly142Arg mutation causing motor neurone disease with prominent premorbid cramps and spasms. J. Neurol. Neurosurg. Psychiatry 87, 1031–1032.
Not in our library10.1136/jnnp-2015-311582
94.
Ito U. Nagasao J. Kawakami E. Oyanagi K. (2007 ). Fate of disseminated dead neurons in the cortical ischemic penumbra: ultrastructure indicating a novel scavenger mechanism of microglia and astrocytes. Stroke 38, 2577–2583.
Not in our library10.1161/strokeaha.107.484394
95.
Bruton’s tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury · 2015
No notice
96.
Jha S. Srivastava S. Y. Brickey W. J. Iocca H. Toews A. Morrison J. P.. (2010 ). The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J. Neurosci. 30, 15811–15820.
Not in our library10.1523/jneurosci.4088-10.2010
97.
Ji J. Kline A. E. Amoscato A. Samhan-Arias A. K. Sparvero L. J. Tyurin V. A.. (2012 ). Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury. Nat. Neurosci. 15, 1407–1413.
Not in our library10.1038/nn.3195
98.
Jian Z. Ding S. Deng H. Wang J. Yi W. Wang L.. (2016 ). Probenecid protects against oxygen-glucose deprivation injury in primary astrocytes by regulating inflammasome activity. Brain Res. 1643, 123–129.
Not in our library10.1016/j.brainres.2016.05.002
99.
Jiang W. Huang Y. He F. Liu J. Li M. Sun T.. (2016 ). Dopamine D1 receptor agonist A-68930 inhibits NLRP3 inflammasome activation, controls Inflammation, and alleviates histopathology in a rat model of spinal cord injury. Spine (Phila Pa 1976) 41, E330–E334.
Not in our library10.1097/brs.0000000000001287
100.
Johann S. Heitzer M. Kanagaratnam M. Goswami A. Rizo T. Weis J.. (2015 ). NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 63, 2260–2273.
Not in our library10.1002/glia.22891
101.
Juliana C. Fernandes-Alnemri T. Kang S. Farias A. Qin F. Alnemri E. S. (2012 ). Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287, 36617–36622.
Not in our library10.1074/jbc.m112.407130
102.
Kamour A. Crichton S. Cooper G. Lupton D. J. Eddleston M. Vale J. A.. (2016 ). Central nervous system toxicity of mefenamic acid overdose compared with other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service. Br. J. Clin. Pharmacol. [Epub ahead of print].
Not in our library10.1111/bcp.13169
103.
Kanneganti T. D. Body-Malapel M. Amer A. Park J. H. Whitfield J. Franchi L.. (2006a ). Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J. Biol. Chem. 281, 36560–36568.
Not in our library10.1074/jbc.m607594200
104.
Kanneganti T. D. Ozören N. Body-Malapel M. Amer A. Park J. H. Franchi L.. (2006b ). Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 440, 233–236.
Not in our library10.1038/nature04517
105.
Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1β secretion in response to ATP · 2016
No notice
106.
Karve I. P. Taylor J. M. Crack P. J. (2016 ). The contribution of astrocytes and microglia to traumatic brain injury. Br. J. Pharmacol. 173, 692–702.
Not in our library10.1111/bph.13125
107.
Kaushal V. Dye R. Pakavathkumar P. Foveau B. Flores J. Hyman B.. (2015 ). Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-β production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 22, 1676–1686.
Not in our library10.1038/cdd.2015.16
108.
NLRP3 Inflammasome: Key Mediator of Neuroinflammation in Murine Japanese Encephalitis · 2012
No notice
109.
Keep R. F. Hua Y. Xi G. (2012 ). Intracerebral haemorrhage: mechanisms of injury and therapeutic targets. Lancet Neurol. 11, 720–731.
Not in our library10.1016/s1474-4422(12)70104-7
110.
Keller M. Rüegg A. Werner S. Beer H. D. (2008 ). Active caspase-1 is a regulator of unconventional protein secretion. Cell 32, 818–831.
Not in our library10.1016/j.cell.2007.12.040
111.
Kettenmann H. Hanisch U.-K. Noda M. Verkhratsky A. (2011 ). Physiology of microglia. Physiol. Rev. 91, 461–553.
Not in our library10.1152/physrev.00011.2010
112.
Kierdorf K. Erny D. Goldmann T. Sander V. Schulz C. Perdiguero E. G.. (2013 ). Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat. Neurosci. 16, 273–280.
Not in our library10.1038/nn.3318
113.
Kim J.-Y. Paton J. C. Briles D. E. Rhee D.-K. Pyo S. (2015 ). Streptococcus pneumoniae induces pyroptosis through the regulation of autophagy in murine microglia. Oncotarget 6, 44161–44178.
Not in our library10.18632/oncotarget.6592
114.
Kingswell R. S. (1981 ). Mefenamic acid overdose. Lancet 2:307.
Not in our library10.1016/s0140-6736(81)90554-7
115.
Apoptosis Is Essential for Neutrophil Functional Shutdown and Determines Tissue Damage in Experimental Pneumococcal Meningitis · 2009
No notice
116.
Kuemmerle-Deschner J. B. Hachulla E. Cartwright R. Hawkins P. N. Tran T. A. Bader-Meunier B.. (2011 ). Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70, 2095–2102.
Not in our library10.1136/ard.2011.152728
117.
Kumar A. Barrett J. P. Alvarez-Croda D. M. Stoica B. A. Faden A. I. Loane D. J. (2016 ). NOX2 drives M1-like microglial/macrophage activation and neurodegeneration following experimental traumatic brain injury. Brain Behav. Immun. 58, 291–309.
Not in our library10.1016/j.bbi.2016.07.158
118.
Kumar H. Kawai T. Akira S. (2011 ). Pathogen recognition by the innate immune system. Int. Rev. Immunol. 30, 16–34.
Not in our library10.3109/08830185.2010.529976
119.
Lalancette-Hébert M. Gowing G. Simard A. Weng Y. C. Kriz J. (2007 ). Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J. Neurosci. 27, 2596–2605.
Not in our library10.1523/jneurosci.5360-06.2007
120.
Lamkanfi M. Mueller J. L. Vitari A. C. Misaghi S. Fedorova A. Deshayes K.. (2009 ). Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J. Cell Biol. 187, 61–70.
Not in our library10.1083/jcb.200903124
121.
Lammerding L. Slowik A. Johann S. Beyer C. Zendedel A. (2016 ). Post-stroke inflammasome expression and regulation in the peri-infarct area by gonadal steroids after transient focal ischemia in the rat brain. Neuroendocrinology 103, 460–475.
Not in our library10.1159/000439435
122.
Lazovic J. Basu A. Lin H.-W. Rothstein R. P. Krady J. K. Smith M. B.. (2005 ). Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke 36, 2226–2231.
Not in our library10.1161/01.str.0000182255.08162.6a
123.
Lee H. M. Kang J. Lee S. J. Jo E. K. (2013 ). Microglial activation of the NLRP3 inflammasome by the priming signals derived from macrophages infected with mycobacteria. Glia 61, 441–452.
Not in our library10.1002/glia.22448
124.
Lee G. S. Subramanian N. Kim A. I. Aksentijevich I. Goldbach-Mansky R. Sacks D. B.. (2012 ). The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP. Nature 492, 123–127.
Not in our library10.1038/nature11588
125.
Levin H. S. Diaz-Arrastia R. R. (2015 ). Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancet Neurol. 14, 506–517.
Not in our library10.1016/s1474-4422(15)00002-2
126.
Li J. Chen J. Mo H. Chen J. Qian C. Yan F.. (2016 ). Minocycline protects against NLRP3 inflammasome-induced inflammation and p53-associated apoptosis in early brain injury after subarachnoid hemorrhage. Mol. Neurobiol. 53, 2668–2678.
Not in our library10.1007/s12035-015-9318-8
127.
Li Q. Hickman M. (2011 ). Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology 279, 1–9.
Not in our library10.1016/j.tox.2010.09.005
128.
Li D. Wang C. Yao Y. Chen L. Liu G. Zhang R.. (2016 ). mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. FASEB J. 30, 3388–3399.
Not in our library10.1096/fj.201600495r
129.
Licastro F. Pedrini S. Caputo L. Annoni G. Davis L. J. Ferri C.. (2000 ). Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer’s disease: peripheral inflammation or signals from the brain? J. Neuroimmunol. 103, 97–102.
Not in our library10.1016/s0165-5728(99)00226-x
130.
Liepinsh E. Barbals R. Dahl E. Sharipo A. Staub E. Otting G. (2003 ). The death-domain fold of the ASC PYRIN domain, presenting a basis for PYRIN/PYRIN recognition. J. Mol. Biol. 332, 1155–1163.
Not in our library10.1016/j.jmb.2003.07.007
131.
Lin C. Chao H. Li Z. Xu X. Liu Y. Bao Z.. (2017 ). Omega-3 fatty acids regulate NLRP3 inflammasome activation and prevent behavior deficits after traumatic brain injury. Exp. Neurol. 290, 115–122.
Not in our library10.1016/j.expneurol.2017.01.005
132.
Liu B. Le K. X. Park M. A. Wang S. Belanger A. P. Dubey S.. (2015 ). In vivo detection of age- and disease-related Increases in neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in wild-type and Alzheimer’s transgenic mice. J. Neurosci. 35, 15716–15730.
Not in our library10.1523/jneurosci.0996-15.2015
133.
Liu H.-D. Li W. Chen Z.-R. Hu Y.-C. Zhang D.-D. Shen W.. (2013 ). Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem. Res. 38, 2072–2083.
Not in our library10.1007/s11064-013-1115-z
134.
Liu X. Zhang Z. Ruan J. Pan Y. Magupalli V. G. Wu H.. (2016 ). Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153–158.
Not in our library10.1038/nature18629
135.
Loane D. J. Byrnes K. R. (2010 ). Role of microglia in neurotrauma. Neurotherapeutics 7, 366–377.
Not in our library10.1016/j.nurt.2010.07.002
136.
Lu B. Nakamura T. Inouye K. Li J. Tang Y. Lundbäck P.. (2012 ). Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488, 670–674.
Not in our library10.1038/nature11290
137.
Lu M. Sun X. L. Qiao C. Liu Y. Ding J. H. Hu G. (2014 ). Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation. Neurobiol. Aging 35, 421–430.
Not in our library10.1016/j.neurobiolaging.2013.08.015
138.
Ma Q. Chen S. Hu Q. Feng H. Zhang J. H. Tang J. (2014 ). NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage. Ann. Neurol. 75, 209–219.
Not in our library10.1002/ana.24070
139.
Ma J. Xiao W. Wang J. Wu J. Ren J. Hou J.. (2016 ). Propofol inhibits NLRP3 inflammasome and attenuates blast-Induced traumatic brain injury in rats. Inflammation 39, 2094–2103.
Not in our library10.1007/s10753-016-0446-8
140.
Mamik M. K. Hui E. Branton W. G. McKenzie B. A. Chisholm J. Cohen E. A.. (2016 ). HIV-1 viral protein R activates NLRP3 inflammasome in microglia: implications for HIV-1 associated neuroinflammation. J. Neuroimmune Pharmacol. [Epub ahead of print].
Not in our library10.1007/s11481-016-9708-3
141.
Marchetti C. Chojnacki J. Toldo S. Mezzaroma E. Tranchida N. Rose S. W.. (2014 ). A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J. Cardiovasc. Pharmacol. 63, 316–322.
Not in our library10.1097/fjc.0000000000000053
142.
Mariathasan S. Weiss D. S. Newton K. McBride J. O’Rourke K. Roose-Girma M.. (2006 ). Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232.
Not in our library10.1038/nature04515
143.
Marina-García N. Franchi L. Kim Y. G. Miller D. McDonald C. Boons G. J.. (2008 ). Pannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2. J. Immunol. 180, 4050–4057.
Not in our library10.4049/jimmunol.180.6.4050
144.
Martinon F. Burns K. Tschopp J. (2002 ). The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol. Cell 10, 417–426.
Not in our library10.1016/s1097-2765(02)00599-3
145.
Martinon F. Pétrilli V. Mayor A. Tardivel A. Tschopp J. (2006 ). Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241.
Not in our library10.1038/nature04516
146.
Masters S. L. Dunne A. Subramanian S. L. Hull R. L. Tannahill G. M. Sharp F. A.. (2010 ). Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat. Immunol. 11, 897–904.
Not in our library10.1038/ni.1935
147.
Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways · 2016
No notice
148.
Masumoto J. Taniguchi S. Ayukawa K. Sarvotham H. Kishino T. Niikawa N.. (1999 ). ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 274, 33835–33838.
Not in our library10.1074/jbc.274.48.33835
149.
Mawhinney L. J. de Rivero Vaccari J. P. Dale G. A. Keane R. W. Bramlett H. M. (2011 ). Heightened inflammasome activation is linked to age-related cognitive impairment in Fischer 344 rats. BMC Neurosci. 12:123.
Not in our library10.1186/1471-2202-12-123
150.
McAfoose J. Baune B. T. (2009 ). Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 33, 355–366.
Not in our library10.1016/j.neubiorev.2008.10.005
151.
Activation of the NLRP3 Inflammasome by IAV Virulence Protein PB1-F2 Contributes to Severe Pathophysiology and Disease · 2013
No notice
152.
Meissner F. Molawi K. Zychlinsky A. (2010 ). Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis. Proc. Natl. Acad. Sci. U S A 107, 13046–13050.
Not in our library10.1073/pnas.1002396107
153.
Meng G. Grabiec A. Vallon M. Ebe B. Hampel S. Bessler W.. (2003 ). Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2. J. Biol. Chem. 278, 39822–39829.
Not in our library10.1074/jbc.m304766200
154.
Michell-Robinson M. A. Touil H. Healy L. M. Owen D. R. Durafourt B. A. Bar-Or A.. (2015 ). Roles of microglia in brain development, tissue maintenance and repair. Brain 138, 1138–1159.
Not in our library10.1093/brain/awv066
155.
Mishra B. B. Rathinam V. A. Martens G. W. Martinot A. J. Kornfeld H. Fitzgerald K. A.. (2013 ). Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β. Nat. Immunol. 14, 52–60.
Not in our library10.1038/ni.2474
156.
Mitchell A. J. Yau B. McQuillan J. A. Ball H. J. Too L. K. Abtin A.. (2012 ). Inflammasome-dependent IFN-γ drives pathogenesis in Streptococcus pneumoniae meningitis. J. Immunol. 189, 4970–4980.
Not in our library10.4049/jimmunol.1201687
157.
Miwa T. Furukawa S. Nakajima K. Furukawa Y. Kohsaka S. (1997 ). Lipopolysaccharide enhances synthesis of brain-derived neurotrophic factor in cultured rat microglia. J. Neurosci. Res. 50, 1023–1029.
Not in our library10.1002/(sici)1097-4547(19971215)50:6<1023::aid-jnr13>3.3.co;2-s
158.
Moss D. W. Bates T. E. (2001 ). Activation of murine microglial cell lines by lipopolysaccharide and interferon-γ causes NO-mediated decreases in mitochondrial and cellular function. Eur. J. Neurosci. 13, 529–538.
Not in our library10.1046/j.1460-9568.2001.01418.x
159.
Murakami T. Ockinger J. Yu J. Byles V. McColl A. Hofer A. M.. (2012 ). Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. U S A 109, 11282–11287.
Not in our library10.1073/pnas.1117765109
160.
Nakahira M. Ahn H. J. Park W. R. Gao P. Tomura M. Park C. S.. (2002 ). Synergy of IL-12 and IL-18 for IFN-γ gene expression: IL-12-induced STAT4 contributes to IFN-γ promoter activation by up-regulating the binding activity of IL-18-induced activator protein 1. J. Immunol. 168, 1146–1153.
Not in our library10.4049/jimmunol.168.3.1146
161.
Nayak D. Roth T. L. McGavern D. B. (2014 ). Microglia development and function. Annu. Rev. Immunol. 32, 367–402.
Not in our library10.1146/annurev-immunol-032713-120240
162.
Newman Z. L. Crown D. Leppla S. H. Moayeri M. (2010 ). Anthrax lethal toxin activates the inflammasome in sensitive rat macrophages. Biochem. Biophys. Res. Commun. 398, 785–789.
Not in our library10.1016/j.bbrc.2010.07.039
163.
Nuvolone M. Sorce S. Schwarz P. Aguzzi A. (2015 ). Prion pathogenesis in the absence of NLRP3/ASC inflammasomes. PLoS One 10:e0117208.
Not in our library10.1371/journal.pone.0117208
164.
O’Connor W. J. Harton J. A. Zhu X. Linhoff M. W. Ting J. P. (2003 ). Cutting edge: CIAS1/cryopyrin/PYPAF1/NALP3/CATERPILLER 1.1 is an inducible inflammatory mediator with NF-κ B suppressive properties. J. Immunol. 171, 6329–6333.
Not in our library10.4049/jimmunol.171.12.6329
165.
Orhan N. Ugur Yilmaz C. Ekizoglu O. Ahishali B. Kucuk M. Arican N.. (2015 ). Effects of β-hydroxybutyrate on brain vascular permeability in rats with traumatic brain injury. Brain Res. 1631, 113–126.
Not in our library10.1016/j.brainres.2015.11.038
166.
Orihuela R. McPherson C. A. Harry G. J. (2016 ). Microglial M1/M2 polarization and metabolic states. Br. J. Pharmacol. 173, 649–665.
Not in our library10.1111/bph.13139
167.
Paolicelli R. C. Bolasco G. Pagani F. Maggi L. Scianni M. Panzanelli P.. (2012 ). Synaptic pruning by microglia is necessary for normal brain development. Science 333, 1456–1458.
Not in our library10.1126/science.1202529
168.
Oligomeric amyloid β induces IL-1β processing via production of ROS: implication in Alzheimer’s disease · 2013
No notice
169.
Pekny M. Nilsson M. (2005 ). Astrocyte activation and reactive gliosis. Glia 50, 427–434.
Not in our library10.1002/glia.20207
170.
Perea G. Navarrete M. Araque A. (2009 ). Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci. 32, 421–431.
Not in our library10.1016/j.tins.2009.05.001
171.
Neuron-glia networks: integral gear of brain function · 2014
No notice
172.
Pétrilli V. Papin S. Dostert C. Mayor A. Martinon F. Tschopp J. (2007 ). Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583–1589.
Not in our library10.1038/sj.cdd.4402195
173.
Pinar A. Dowling J. K. Bitto N. J. Robertson A. B. Latz E. Stewart C. R.. (2016 ). PB1–F2 derived from avian influenza a virus H7N9 induces inflammation via activation of the NLRP3 inflammasome. J. Biol. Chem. 292, 826–836.
Not in our library10.1074/jbc.m116.756379
174.
Py B. F. Kim M. S. Vakifahmetoglu-Norberg H. Yuan J. (2013 ). Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49, 331–338.
Not in our library10.1016/j.molcel.2012.11.009
175.
Qin M. Landriscina A. Rosen J. M. Wei G. Kao S. Olcott W.. (2015 ). Nitric Oxide-releasing nanoparticles prevent propionibacterium acnes-induced inflammation by both clearing the organism and inhibiting microbial stimulation of the innate immune response. J. Invest. Dermatol. 135, 2723–2731.
Not in our library10.1038/jid.2015.277
176.
Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain · 2013
No notice
177.
Rathinam V. A. Jiang Z. Waggoner S. N. Sharma S. Cole L. E. Waggoner L.. (2010 ). The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat. Immunol. 11, 395–402.
Not in our library10.1038/ni.1864
178.
Rathinam V. A. Vanaja S. K. Fitzgerald K. A. (2012 ). Regulation of inflammasome signaling. Nat. Immunol. 13, 333–342.
Not in our library10.1038/ni.2237
179.
Redmond A. D. (1981 ). Dyskinesia induced by mefanimic acid? J. R. Soc. Med. 74, 558–559.
Not in our library10.1177/014107688107400733
180.
Ribes S. Ebert S. Czesnik D. Regen T. Zeug A. Bukowski S.. (2009 ). Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. Infect. Immun. 77, 557–564.
Not in our library10.1128/iai.00903-08
181.
Rock R. B. Gekker G. Hu S. Sheng W. S. Cheeran M. Lokensgard J. R.. (2004 ). Role of microglia in central nervous system infections. Clin. Microbiol. Rev. 17, 942–964.
Not in our library10.1128/cmr.17.4.942-964.2004
182.
Roed C. Engsig F. N. Omland L. H. Skinhoj P. Obel N. (2012 ). Long-term mortality in patients diagnosed with Listeria monocytogenes meningitis: a Danish nationwide cohort study. J. Infect. 64, 34–40.
Not in our library10.1016/j.jinf.2011.10.003
183.
Rosenzweig H. L. Planck S. R. Rosenbaum J. T. (2011 ). NLRs in immune privileged sites. Curr. Opin. Pharmacol. 11, 423–428.
Not in our library10.1016/j.coph.2011.07.002
184.
Saijo K. Crotti A. Glass C. K. (2013 ). Regulation of microglia activation and deactivation by nuclear receptors. Glia 61, 104–111.
Not in our library10.1002/glia.22423
185.
Saitoh T. Fujita N. Jang M. H. Uematsu S. Yang B. G. Satoh T.. (2008 ). Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature 456, 264–268.
Not in our library10.1038/nature07383
186.
The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer’s disease · 2016
No notice
187.
Schmid-Burgk J. L. Chauhan D. Schmidt T. Ebert T. S. Reinhardt J. Endl E.. (2016 ). A genome-wide CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) screen identifies NEK7 as an essential component of NLRP3 inflammasome activation. J. Biol. Chem. 291, 103–109.
Not in our library10.1074/jbc.c115.700492
188.
Sehba F. A. Hou J. Pluta R. M. Zhang J. H. (2012 ). The importance of early brain injury after subarachnoid hemorrhage. Prog. Neurobiol. 97, 14–37.
Not in our library10.1016/j.pneurobio.2012.02.003
189.
Shah V. B. Huang Y. Keshwara R. Ozment-Skelton T. Williams D. L. Keshvara L. (2008 ). β-glucan activates microglia without inducing cytokine production in Dectin-1-dependent manner. J. Immunol. 180, 2777–2785.
Not in our library10.4049/jimmunol.180.5.2777
190.
Shao A. Wu H. Hong Y. Tu S. Sun X. Wu Q.. (2016 ). Hydrogen-rich saline atenuated subarachnoid hemorrhage-induced early brain injury in rats by suppressing inflammatory response: possible involvement of NF-κB pathway and NLRP3 inflammasome. Mol. Neurobiol. 53, 3462–3476.
Not in our library10.1007/s12035-015-9242-y
191.
Sharp F. A. Ruane D. Claass B. Creagh E. Harris J. Malyala P.. (2009 ). Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl. Acad. Sci. U S A 106, 870–875.
Not in our library10.1073/pnas.0804897106
192.
Shi F. Kouadir M. Yang Y. (2015 ). NALP3 inflammasome activation in protein misfolding diseases. Life Sci. 135, 9–14.
Not in our library10.1016/j.lfs.2015.05.011
193.
Shi C. S. Shenderov K. Huang N. N. Kabat J. Abu-Asab M. Fitzgerald K. A.. (2012 ). Activation of autophagy by inflammatory signals limits IL-1β production by targeting ubiquitinated inflammasomes for destruction. Nat. Immunol. 13, 255–263.
Not in our library10.1038/ni.2215
194.
Shi H. Wang Y. Li X. Zhan X. Tang M. Fina M.. (2016 ). NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat. Immunol. 17, 250–258.
Not in our library10.1038/ni.3333
195.
Shi F. Yang L. Kouadir M. Yang Y. Wang J. Zhou X.. (2012 ). The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation. J. Neuroinflammation 9:73.
Not in our library10.1186/1742-2094-9-73
196.
Shi J. Zhao Y. Wang K. Shi X. Wang Y. Huang H.. (2015 ). Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665.
Not in our library10.1038/nature15514
197.
Shi J. Q. Zhang C. C. Sun X. L. Cheng X. X. Wang J. B. Zhang Y. D.. (2013 ). Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-κB and NLRP3 inflammasome activation. CNS Neurosci. Ther. 19, 262–268.
Not in our library10.1016/j.jalz.2013.04.112
198.
Shrivastava S. K. Dalko E. Delcroix-Genete D. Herbert F. Cazenave P. A. Pied S. (2017 ). Uptake of parasite-derived vesicles by astrocytes and microglial phagocytosis of infected erythrocytes may drive neuroinflammation in cerebral malaria. Glia 65, 75–92.
Not in our library10.1002/glia.23075
199.
Sifringer M. Stefovska V. Endesfelder S. Stahel P. F. Genz K. Dzietko M.. (2007 ). Activation of caspase-1 dependent interleukins in developmental brain trauma. Neurobiol. Dis. 25, 614–622.
Not in our library10.1016/j.nbd.2006.11.003
200.
Silver J. Miller J. H. (2004 ). Regeneration beyond the glial scar. Nat. Rev. Neurosci. 5, 146–156.
Not in our library10.1038/nrn1326
201.
Silverman W. R. de Rivero Vaccari J. P. Locovei S. Qiu F. Carlsson S. K. Sceme S. E.. (2009 ). The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J. Biol. Chem. 284, 18143–18151.
Not in our library10.1074/jbc.m109.004804
202.
Sofroniew M. V. (2005 ). Reactive astrocytes in neural repair and protection. Neuroscientist 11, 400–407.
Not in our library10.1177/1073858405278321
203.
Sofroniew M. V. (2009 ). Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 32, 638–647.
Not in our library10.1016/j.tins.2009.08.002
204.
Sosunov A. A. Wu X. Tsankova N. M. Guilfoyle E. McKhann G. M. II. Goldman J. E. (2014 ). Phenotypic heterogeneity and plasticity of isocortical and hippocampal astrocytes in the human brain. J. Neurosci. 34, 2285–2298.
Not in our library10.1523/jneurosci.4037-13.2014
205.
Srinivasula S. M. Poyet J. L. Razmara M. Datta P. Zhang Z. Alnemri E. S. (2002 ). The PYRIN-CARD protein ASC is an activating adaptor for caspase-1. J. Biol. Chem. 277, 21119–21122.
Not in our library10.1074/jbc.c200179200
206.
Subramanian N. Natarajan K. Clatworthy M. R. Wang Z. Germain R. N. (2013 ). The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 153, 348–361.
Not in our library10.1016/j.cell.2013.02.054
207.
Sutterwala F. S. Mijares L. A. Li L. Ogura Y. Kazmierczak B. I. Flavell R. A. (2007 ). Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome. J. Exp. Med. 204, 3235–3245.
Not in our library10.1084/jem.20071239
208.
Sutterwala F. S. Ogura Y. Szczepanik M. Lara-Tejero M. Lichtenberger G. S. Grant E. P.. (2006 ). Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24, 317–327.
Not in our library10.1016/j.immuni.2006.02.004
209.
Szretter K. J. Samuel M. A. Gilfillan S. Fuchs A. Colonna M. Diamond M. S. (2009 ). The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J. Virol. 83, 9329–9338.
Not in our library10.1128/jvi.00836-09
210.
Tahara K. Kim H. D. Jin J. J. Maxwell J. A. Li L. Fukuchi K. (2006 ). Role of toll-like receptor signalling in Aβ uptake and clearance. Brain 129, 3006–3019.
Not in our library10.1093/brain/awl249
211.
Tang S. C. Wang Y. C. Li Y. I. Lin H. C. Manzanero S. Hsieh Y. H.. (2013 ). Functional role of soluble receptor for advanced glycation end products in stroke. Arterioscler. Thromb. Vasc. Biol. 33, 585–594.
Not in our library10.1161/atvbaha.112.300523
212.
Tan M. S. Tan L. Jiang T. Zhu X. C. Wang H. F. Jia C. D.. (2014 ). Amyloid-β induces NLRP1-dependent neuronal pyroptosis in models of Alzheimer’s disease. Cell Death Dis. 5:e1382.
Not in our library10.1038/cddis.2014.348
213.
Tan M. S. Yu J. T. Jiang T. Zhu X. C. Wang H. F. Zhang W.. (2013 ). NLRP3 polymorphisms are associated with late-onset Alzheimer’s disease in Han Chinese. J. Neuroimmunol. 265, 91–95.
Not in our library10.1016/j.jneuroim.2013.10.002
214.
Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition · 2016
No notice
215.
Thakkar R. Wang R. Sareddy G. Wang J. Thiruvaiyaru D. Vadlamudi R.. (2016 ). NLRP3 inflammasome activation in the brain after global cerebral ischemia and regulation by 17β-estradiol. Oxid. Med. Cell. Longev. 2016:8309031.
Not in our library10.1155/2016/8309031
216.
Thomas P. G. Dash P. Aldridge J. R. Jr. Ellebedy A. H. Reynolds C. Funk A. J.. (2009 ). The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30, 566–575.
Not in our library10.1016/j.immuni.2009.02.006
217.
Thønnings S. Knudsen J. D. Schønheyder H. C. Søgaard M. Arpi M. Gradel K. O.. (2016 ). Antibiotic treatment and mortality in patients with Listeria monocytogenes meningitis or bacteraemia. Clin. Microbiol. Infect. 22, 725–730.
Not in our library10.1016/j.cmi.2016.06.006
218.
The Physical Relationship between Infectivity and Prion Protein Aggregates Is Strain-Dependent · 2010
No notice
219.
Toldo S. Mezzaroma E. McGeough M. D. Peña C. A. Marchetti C. Sonnino C.. (2015 ). Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart. Cardiovasc. Res. 105, 203–212.
Not in our library10.1093/cvr/cvu259
220.
Tribouillard-Tanvier D. Striebel J. F. Peterson K. E. Chesebro B. (2009 ). Analysis of protein levels of 24 cytokines in scrapie agent-infected brain and glial cell cultures from mice differing in prion protein expression levels. J. Virol. 83, 11244–11253.
Not in our library10.1128/jvi.01413-09
221.
Tsuda T. Munthasser S. Fraser P. E. Percy M. E. Rainero I. Vaula G.. (1994 ). Analysis of the functional effects of a mutation in SOD1 associated with familial amyotrophic lateral sclerosis. Neuron 13, 727–736.
Not in our library10.1016/0896-6273(94)90039-6
222.
Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS · 2014
No notice
223.
Wang J. Doré S. (2007 ). Inflammation after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 27, 894–908.
Not in our library10.1038/sj.jcbfm.9600403
224.
Wang X. Li R. Wang X. Fu Q. Ma S. (2015 ). Umbelliferone ameliorates cerebral ischemia–reperfusion injury via upregulating the PPAR gamma expression and suppressing TXNIP/NLRP3 inflammasome. Neurosci. Lett. 600, 182–187.
Not in our library10.1016/j.neulet.2015.06.016
225.
Warren S. E. Mao D. P. Rodriguez A. E. Miao E. A. Aderem A. (2008 ). Multiple Nod-like receptors activate caspase 1 during Listeria monocytogenes infection. J. Immunol. 180, 7558–7564.
Not in our library10.4049/jimmunol.180.11.7558
226.
Werner C. Engelhard K. (2007 ). Pathophysiology of traumatic brain injury. Br. J. Anaesth. 99, 4–9.
Not in our library10.1093/bja/aem131
227.
White C. S. Lawrence C. B. Brough D. Rivers-Auty J. (2017 ). Inflammmasomes as therapeutic targets for Alzheimer’s disease. Brain Pathol. 27, 223–234.
Not in our library10.1111/bpa.12478
228.
Willingham S. B. Bergstralh D. T. O’Connor W. Morrison A. C. Taxman D. J. Duncan J. A.. (2007 ). Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell Host Microbe 2, 147–159.
Not in our library10.1016/j.chom.2007.07.009
229.
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation · 2010
No notice
230.
Witiw C. D. Fehlings M. G. (2015 ). Acute spinal cord injury. J. Spinal Disord. Tech. 28, 202–210.
Not in our library10.1097/bsd.0000000000000287
231.
Witten I. B. Steinberg E. E. Lee S. Y. Davidson T. J. Zalocusky K. A. Brodsky M.. (2011 ). Recombinase-driver rat lines: tools, techniques and optogenetic application to dopamine-mediated reinforcement. Neuron 72, 721–733.
Not in our library10.1016/j.neuron.2011.10.028
232.
Wu J. Fernandes-Alnemri T. Alnemri E. S. (2010 ). Involvement of the AIM2, NLRC4 and NLRP3 inflammasomes in caspase-1 activation by Listeria monocytogenes. J. Clin. Immunol. 30, 693–702.
Not in our library10.1007/s10875-010-9425-2
233.
Xiao M. Li L. Li C. Liu L. Yu Y. Ma L. (2016 ). 3,4-methylenedioxy-β-nitrostyrene ameliorates experimental burn wound progression by inhibiting the NLRP3 inflammasome activation. Plast. Reconstr. Surg. 137, 566e–575e.
Not in our library10.1097/01.prs.0000479972.06934.83
234.
Xian W. Wu Y. Xiong W. Li L. Li T. Pan S.. (2016 ). The pro-resolving lipid mediator Maresin 1 protects against cerebral ischemia/reperfusion injury by attenuating the pro-inflammatory response. Biochem. Biophys. Res. Commun. 472, 175–181.
Not in our library10.1016/j.bbrc.2016.02.090
235.
Xie G. Tian W. Wei T. Liu F. (2015 ). The neuroprotective effects of β-hydroxybutyrate on Aβ-injected rat hippocampus in vivo and in Aβ-treated PC-12 cells in vitro. Free Radic. Res. 49, 139–150.
Not in our library10.3109/10715762.2014.987274
236.
Xiong Y. Mahmood A. Chopp M. (2013 ). Animal models of traumatic brain injury. Nat. Rev. Neurosci. 14, 128–142.
Not in our library10.1038/nrn3407
237.
Yang F. Wang Z. Wei X. Han H. Meng X. Zhang Y.. (2014 ). NLRP3 deficiency ameliorates neurovascular damage in experimental ischemic stroke. J. Cereb. Blood Flow Metab. 34, 660–667.
Not in our library10.1038/jcbfm.2013.242
238.
Yang Z. Zhong L. Xian R. Yuan B. (2015 ). MicroRNA-223 regulates inflammation and brain injury via feedback to NLRP3 inflammasome after intracerebral hemorrhage. Mol. Immunol. 65, 267–276.
Not in our library10.1016/j.molimm.2014.12.018
239.
Yatsiv I. Morganti-Kossmann M. C. Perez D. Dinarello C. A. Novick D. Rubinstein M.. (2002 ). Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J. Cereb. Blood Flow Metab. 22, 971–978.
Not in our library10.1097/00004647-200208000-00008
240.
Yin Y. Yan Y. Jiang X. Mai J. Chen N. C. Wang H.. (2009 ). Inflammasomes are differentially expressed in cardiovascular and other tissues. Int. J. Immunopathol. Pharmacol. 22, 311–322.
Not in our library10.1177/039463200902200208
241.
Youm Y. H. Nguyen K. Y. Grant R. W. Goldberg E. L. Bodogai M. Kim D.. (2015 ). The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269.
Not in our library10.1038/nm.3804
242.
Yuan B. Shen H. Lin L. Su T. Zhong S. Yang Z. (2015 ). Recombinant adenovirus encoding NLRP3 RNAi attenuate inflammation and brain injury after intracerebral hemorrhage. J. Neuroinflammation 287, 71–75.
Not in our library10.1016/j.jneuroim.2015.08.002
243.
Yu M. Zhang K. Qi W. Huang Z. Ye J. Ma Y.. (2014 ). Expression pattern of NLRP3 and its related cytokines in the lung and brain of avian influenza virus H9N2 infected BALB/c mice. Virol. J. 11:229.
Not in our library10.1186/s12985-014-0229-5
244.
Zendedel A. Johann S. Mehrabi S. Joghataei M. Hassanzadeh G. Kipp M.. (2016 ). Activation and regulation of NLRP3 inflammasome by intrathecal application of SDF-1a in a spinal cord injury model. Mol. Neurobiol. 53, 3063–3075.
Not in our library10.1007/s12035-015-9203-5
245.
Zhang Y. Barres B. A. (2010 ). Astrocyte heterogeneity: an underappreciated topic in neurobiology. Curr. Opin. Neurobiol. 20, 588–594.
Not in our library10.1016/j.conb.2010.06.005
246.
Zhang Q. Bian G. Chen P. Liu L. Yu C. Liu F.. (2016 ). Aldose reductase regulates microglia/macrophages polarization through the cAMP response element-binding protein after spinal cord injury in mice. Mol. Neurobiol. 53, 662–676.
Not in our library10.1007/s12035-014-9035-8
247.
Zhao W. Beers D. R. Bell S. Wang J. Wen S. Baloh R. H.. (2015 ). TDP-43 activates microglia through NF-κB and NLRP3 inflammasome. Exp. Neurol. 273, 24–35.
Not in our library10.1016/j.expneurol.2015.07.019
248.
Zhou R. Tardivel A. Thorens B. Choi I. Tschopp J. (2010 ). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol. 11, 136–140.
Not in our library10.1038/ni.1831
249.
Zhou R. Yazdi A. S. Menu P. Tschopp J. (2011 ). A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225.
Not in our library10.1038/nature09663

Cited by papers we hold 21

Identifying pyroptosis- and inflammation-related genes in spinal cord injury based on bioinformatics analysis · 2025
Not checked
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets · 2023
No notice
An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer’s disease · 2023
No notice
Paeonol regulates NLRP3 inflammasomes and pyroptosis to alleviate spinal cord injury of rat · 2022
Not checked
Anti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases · 2022
No notice
The Role of NF-κB Triggered Inflammation in Cerebral Ischemia · 2021
Not checked
Microglia and Neuroinflammation: What Place for P2RY12? · 2021
No notice
Pyroptosis: mechanisms and diseases · 2021
No notice
Inhibition of the NLRP3-inflammasome prevents cognitive deficits in experimental autoimmune encephalomyelitis mice via the alteration of astrocyte phenotype · 2020
No notice
Neuron-Astrocyte Interactions in Parkinson’s Disease · 2020
No notice
The Gut-Brain Axis: How Microbiota and Host Inflammasome Influence Brain Physiology and Pathology · 2020
No notice
Gut microbiota from NLRP3-deficient mice ameliorates depressive-like behaviors by regulating astrocyte dysfunction via circHIPK2 · 2019
No notice
Alzheimer’s disease-associated (hydroxy)methylomic changes in the brain and blood · 2019
No notice
Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in in vitro and in vivo models of sepsis · 2019
No notice
The Crohn’s Disease Risk Factor IRGM Limits NLRP3 Inflammasome Activation by Impeding Its Assembly and by Mediating Its Selective Autophagy · 2019
No notice
Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome · 2019
No notice
Diet in Parkinson's Disease: Critical Role for the Microbiome · 2019
No notice
Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines · 2018
No notice
PM2.5 exposure aggravates oligomeric amyloid beta-induced neuronal injury and promotes NLRP3 inflammasome activation in an in vitro model of Alzheimer’s disease · 2018
No notice
Role of the NLRP3 inflammasome in cancer · 2018
No notice

and 1 more

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.